New York City-based Weill Cornell and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center will add Aclarion’s Nociscan tool, according to an April 8 news release.
Weill Cornell and Aclarion established a commercial agreement, and Nociscan will be used as part of the trial “A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate (BMAC) for Osteoarthritis and Degenerative Disc Disease.”
The study will investigate whether the dose and quantity of bone marrow aspirate stem cell concentrate for osteoarthritis and degenerative disc disease in the spine. Some patients in the study will be eligible for Nociscan, an AI tool to help physicians identify the source of chronic low back pain.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
